Simvastatin protects heart from pressure overload injury by inhibiting excessive autophagy

  • Feifei Su
  • , Miaoqian Shi
  • , Jian Zhang
  • , Qiangsun Zheng
  • , Dongwei Zhang
  • , Wei Zhang
  • , Haichang Wang
  • , Xue Li

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Abstract

Cardiac hypertrophy is an independent predictor of cardiovascular morbidity and mortality. To identify the mechanisms by which simvastatin inhibits cardiac hypertrophy induced by pressure overload, we determined effects of simvastatin on 14-3-3 protein expression and autophagic activity. Simvastatin was administered intragastrically to Sprague-Dawley (SD) rats before abdominal aortic banding (AAB). Neonatal rat cardiomyocytes (NRCs) were treated with simvastatin before angiotensin II (AngII) stimulation. 14-3-3, LC3, and p62 protein levels were determined by western blot. Autophagy was also measured by the double-labeled red fluorescent protein-green fluorescent protein autophagy reporter system. Simvastatin alleviated excessive autophagy, characterized by a high LC3II/LC3I ratio and low level of p62, and blunted cardiac hypertrophy while increasing 14-3-3 protein expression in rats that had undergone AAB. In addition, it increased 14-3-3 expression and inhibited excessive autophagy in NRCs exposed to AngII. Our study demonstrated that simvastatin may inhibit excessive autophagy, increase 14-3-3 expression, and finally exert beneficial effects on cardioprotection against pressure overload.

Original languageEnglish
Pages (from-to)1508-1516
Number of pages9
JournalInternational Journal of Medical Sciences
Volume15
Issue number13
DOIs
StatePublished - 20 Oct 2018
Externally publishedYes

Keywords

  • 14-3-3
  • Autophagy
  • Hydroxymethylglutaryl-CoA reductase inhibitors
  • Hypertrophy
  • Simvastatin

Fingerprint

Dive into the research topics of 'Simvastatin protects heart from pressure overload injury by inhibiting excessive autophagy'. Together they form a unique fingerprint.

Cite this